2,905
Views
12
CrossRef citations to date
0
Altmetric
Original Articles

Characteristics and experiences of buprenorphine-naloxone use among polysubstance users

, MSW, LCSW, , PhD, , MA, MD, PhD & , BA
Pages 595-603 | Received 08 May 2017, Accepted 03 Apr 2018, Published online: 25 Apr 2018

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (3)

Stephanie K. Rubel, Matthew Eisenstat, Jessica Wolff, Michael Calevski & Sasha Mital. (2023) Scope of, Motivations for, and Outcomes Associated with Buprenorphine Diversion in the United States: A Scoping Review. Substance Use & Misuse 58:5, pages 685-697.
Read now
Kirsten E. Smith, Amanda M. Bunting, Robert Walker, Martin T. Hall, Oliver Grundmann & Olivia Castillo. (2019) Non-Prescribed Buprenorphine Use Mediates the Relationship between Heroin Use and Kratom Use among a Sample of Polysubstance Users. Journal of Psychoactive Drugs 51:4, pages 311-322.
Read now
Edward V. Nunes. (2018) Buprenorphine in the real world: coming to terms with misuse and diversion. The American Journal of Drug and Alcohol Abuse 44:6, pages 576-577.
Read now

Articles from other publishers (9)

Dara M. Kusic, Jessica Heil, Stefan Zajic, Andrew Brangan, Oluseun Dairo, Stacey Heil, Gerald Feigin, Sherri Kacinko, Russell J. Buono, Thomas N. Ferraro, Rachel Rafeq, Rachel Haroz, Kaitlan Baston, Elliot Bodofsky, Michael Sabia, Matthew Salzman, Alissa Resch, Jozef Madzo, Laura B. Scheinfeldt, Jean-Pierre J. Issa & Jaroslav Jelinek. (2023) Postmortem toxicology findings from the Camden Opioid Research Initiative. PLOS ONE 18:11, pages e0292674.
Crossref
Mance E. Buttram, Steven P. Kurtz, Zachary R. Margolin & Stevan Geoffrey Severtson. (2021) Increasing rates of buprenorphine diversion in the United States, 2002 to 2019. Pharmacoepidemiology and Drug Safety 30:11, pages 1514-1519.
Crossref
TK Logan, Jennifer Cole & Robert Walker. (2020) Examining Recovery Program Participants by Gender: Program Completion, Relapse, and Multidimensional Status 12 Months After Program Entry. Journal of Drug Issues 50:4, pages 436-454.
Crossref
Richard J. Bodnar. (2020) Endogenous Opiates and Behavior: 2018. Peptides 132, pages 170348.
Crossref
Jillian L. Kyzer & Cody J. Wenthur. (2020) Classics in Chemical Neuroscience: Buprenorphine. ACS Chemical Neuroscience 11:10, pages 1385-1399.
Crossref
Kirsten E. Smith, Martha D. Tillson, Michele Staton & Erin M. Winston. (2020) Characterization of diverted buprenorphine use among adults entering corrections-based drug treatment in Kentucky. Drug and Alcohol Dependence 208, pages 107837.
Crossref
Raminta Daniulaityte, Ramzi W. Nahhas, Sydney Silverstein, Silvia Martins, Angela Zaragoza, Avery Moeller & Robert G. Carlson. (2019) Patterns of non-prescribed buprenorphine and other opioid use among individuals with opioid use disorder: A latent class analysis. Drug and Alcohol Dependence 204, pages 107574.
Crossref
Matisyahu Shulman, Jonathan M. Wai & Edward V. Nunes. (2019) Buprenorphine Treatment for Opioid Use Disorder: An Overview. CNS Drugs 33:6, pages 567-580.
Crossref
Stephanie K. Rubel, Matthew Eisenstat, Jessica Wolff, Michael Calevski & Sasha Mital. (2022) Scope of, Motivations for, And Outcomes of Diverted Buprenorphine Among People Using Buprenorphine: A Scoping Review. SSRN Electronic Journal.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.